 Raj Shah
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiopancreatography, Endoscopic Retrograde | 45 | 2025 | 213 | 10.330 |
Why?
| | Endoscopy, Digestive System | 22 | 2024 | 136 | 6.490 |
Why?
| | Pancreatic Ducts | 22 | 2024 | 85 | 6.350 |
Why?
| | Pancreatic Diseases | 14 | 2024 | 72 | 4.950 |
Why?
| | Pancreatitis, Chronic | 12 | 2024 | 58 | 4.660 |
Why?
| | Calculi | 8 | 2022 | 16 | 4.050 |
Why?
| | Bile Duct Neoplasms | 13 | 2021 | 124 | 3.550 |
Why?
| | Endosonography | 25 | 2024 | 156 | 3.510 |
Why?
| | Lithotripsy | 11 | 2024 | 48 | 3.340 |
Why?
| | Stents | 20 | 2024 | 527 | 3.200 |
Why?
| | Cholangitis, Sclerosing | 8 | 2022 | 75 | 2.880 |
Why?
| | Pancreatic Neoplasms | 20 | 2024 | 938 | 2.700 |
Why?
| | Cholangiocarcinoma | 7 | 2021 | 104 | 2.540 |
Why?
| | Drainage | 10 | 2024 | 173 | 2.100 |
Why?
| | Bile Ducts, Intrahepatic | 5 | 2021 | 78 | 1.970 |
Why?
| | Bile Ducts | 9 | 2019 | 71 | 1.870 |
Why?
| | Biliary Tract Surgical Procedures | 4 | 2021 | 26 | 1.840 |
Why?
| | Endoscopy, Gastrointestinal | 12 | 2023 | 228 | 1.790 |
Why?
| | Constriction, Pathologic | 15 | 2022 | 245 | 1.690 |
Why?
| | Pancreatic Pseudocyst | 5 | 2024 | 17 | 1.320 |
Why?
| | Gallstones | 4 | 2018 | 33 | 1.320 |
Why?
| | Microscopy, Confocal | 8 | 2021 | 325 | 1.270 |
Why?
| | Pancreas | 6 | 2021 | 329 | 1.240 |
Why?
| | Biliary Tract Diseases | 4 | 2016 | 39 | 1.230 |
Why?
| | Cholestasis | 7 | 2021 | 235 | 1.120 |
Why?
| | Endoscopes | 3 | 2017 | 17 | 1.100 |
Why?
| | Aged | 51 | 2025 | 23961 | 1.040 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2016 | 289 | 1.030 |
Why?
| | Middle Aged | 59 | 2025 | 33479 | 1.030 |
Why?
| | Treatment Outcome | 30 | 2025 | 10811 | 0.980 |
Why?
| | Retrospective Studies | 30 | 2025 | 15657 | 0.900 |
Why?
| | Adenocarcinoma | 7 | 2023 | 940 | 0.900 |
Why?
| | Pancreatitis | 5 | 2024 | 134 | 0.880 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 7 | 2019 | 56 | 0.880 |
Why?
| | Endoscopy | 4 | 2015 | 318 | 0.870 |
Why?
| | Endoscopes, Gastrointestinal | 8 | 2013 | 14 | 0.870 |
Why?
| | Humans | 108 | 2025 | 137585 | 0.840 |
Why?
| | Duodenal Neoplasms | 1 | 2023 | 23 | 0.840 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2023 | 30 | 0.830 |
Why?
| | Ampulla of Vater | 1 | 2023 | 42 | 0.830 |
Why?
| | Choledochal Cyst | 2 | 2020 | 19 | 0.820 |
Why?
| | Laparoscopy | 4 | 2021 | 466 | 0.810 |
Why?
| | Hepatic Encephalopathy | 1 | 2022 | 21 | 0.780 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2016 | 80 | 0.780 |
Why?
| | Male | 64 | 2025 | 67762 | 0.780 |
Why?
| | Pancreatectomy | 3 | 2021 | 253 | 0.770 |
Why?
| | Gastrointestinal Tract | 1 | 2025 | 195 | 0.770 |
Why?
| | Catheterization | 8 | 2024 | 179 | 0.760 |
Why?
| | Female | 66 | 2025 | 73304 | 0.760 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2022 | 44 | 0.750 |
Why?
| | Cholangitis | 1 | 2022 | 21 | 0.750 |
Why?
| | Hypertension, Portal | 1 | 2022 | 64 | 0.740 |
Why?
| | Adenoma | 2 | 2023 | 230 | 0.740 |
Why?
| | End Stage Liver Disease | 1 | 2022 | 82 | 0.700 |
Why?
| | Calcinosis | 2 | 2019 | 235 | 0.670 |
Why?
| | Cytodiagnosis | 1 | 2020 | 33 | 0.670 |
Why?
| | Intestine, Small | 2 | 2019 | 156 | 0.630 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2020 | 317 | 0.610 |
Why?
| | Artificial Intelligence | 1 | 2022 | 279 | 0.590 |
Why?
| | Adult | 36 | 2025 | 37929 | 0.590 |
Why?
| | Lithotripsy, Laser | 2 | 2015 | 8 | 0.580 |
Why?
| | Aged, 80 and over | 18 | 2025 | 7635 | 0.580 |
Why?
| | Quality of Life | 4 | 2024 | 2892 | 0.580 |
Why?
| | Aneurysm, False | 1 | 2018 | 48 | 0.550 |
Why?
| | Prospective Studies | 23 | 2024 | 7604 | 0.540 |
Why?
| | Liver Neoplasms | 1 | 2023 | 786 | 0.540 |
Why?
| | Disposable Equipment | 1 | 2017 | 19 | 0.540 |
Why?
| | Foreign Bodies | 1 | 2018 | 104 | 0.540 |
Why?
| | Laser Therapy | 1 | 2018 | 130 | 0.520 |
Why?
| | Polyethylene | 1 | 2016 | 14 | 0.490 |
Why?
| | Biopsy | 6 | 2018 | 1129 | 0.490 |
Why?
| | Gallbladder Diseases | 1 | 2015 | 12 | 0.480 |
Why?
| | Gastroenterology | 4 | 2019 | 180 | 0.480 |
Why?
| | Pancreatic Juice | 1 | 2014 | 2 | 0.460 |
Why?
| | Gastrointestinal Diseases | 5 | 2022 | 209 | 0.460 |
Why?
| | Learning Curve | 5 | 2019 | 72 | 0.450 |
Why?
| | Sphincterotomy, Endoscopic | 4 | 2019 | 28 | 0.440 |
Why?
| | CA-19-9 Antigen | 1 | 2014 | 22 | 0.440 |
Why?
| | Biomarkers, Tumor | 2 | 2014 | 1276 | 0.440 |
Why?
| | Metals | 4 | 2023 | 136 | 0.430 |
Why?
| | Postoperative Complications | 3 | 2022 | 2654 | 0.430 |
Why?
| | Sensitivity and Specificity | 9 | 2021 | 1946 | 0.420 |
Why?
| | Hemorrhage | 1 | 2018 | 722 | 0.410 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2013 | 39 | 0.400 |
Why?
| | Ultrasonography, Interventional | 3 | 2022 | 141 | 0.400 |
Why?
| | Pancreatitis, Acute Necrotizing | 2 | 2023 | 13 | 0.380 |
Why?
| | Follow-Up Studies | 12 | 2021 | 5131 | 0.380 |
Why?
| | Predictive Value of Tests | 7 | 2017 | 2031 | 0.370 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 28 | 0.360 |
Why?
| | Liver Diseases | 1 | 2014 | 315 | 0.350 |
Why?
| | Clinical Competence | 5 | 2019 | 1118 | 0.340 |
Why?
| | Young Adult | 9 | 2025 | 13209 | 0.340 |
Why?
| | Biliary Tract Neoplasms | 3 | 2016 | 30 | 0.340 |
Why?
| | Foreign-Body Migration | 2 | 2006 | 34 | 0.300 |
Why?
| | Natural Orifice Endoscopic Surgery | 3 | 2018 | 34 | 0.290 |
Why?
| | Needles | 3 | 2019 | 59 | 0.290 |
Why?
| | Pancreatic Cyst | 3 | 2018 | 60 | 0.290 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2008 | 132 | 0.290 |
Why?
| | B7-1 Antigen | 1 | 2008 | 58 | 0.280 |
Why?
| | Video Recording | 4 | 2016 | 180 | 0.280 |
Why?
| | Fluorouracil | 4 | 2020 | 208 | 0.270 |
Why?
| | Bile Ducts, Extrahepatic | 2 | 2020 | 22 | 0.270 |
Why?
| | Gallbladder | 2 | 2022 | 19 | 0.260 |
Why?
| | Dilatation | 2 | 2018 | 67 | 0.260 |
Why?
| | Abdominal Pain | 4 | 2023 | 145 | 0.250 |
Why?
| | Adolescent | 11 | 2025 | 21513 | 0.250 |
Why?
| | Cholelithiasis | 3 | 2015 | 38 | 0.250 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 8 | 0.230 |
Why?
| | Celiac Plexus | 1 | 2024 | 6 | 0.230 |
Why?
| | Hemostatic Techniques | 1 | 2005 | 46 | 0.230 |
Why?
| | Indomethacin | 1 | 2024 | 81 | 0.220 |
Why?
| | Catheters | 2 | 2015 | 73 | 0.220 |
Why?
| | Peritoneal Neoplasms | 1 | 2005 | 93 | 0.220 |
Why?
| | Ambulatory Care Facilities | 1 | 2006 | 232 | 0.220 |
Why?
| | Guanidines | 1 | 2023 | 39 | 0.220 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 528 | 0.210 |
Why?
| | Equipment Design | 9 | 2013 | 522 | 0.210 |
Why?
| | Esters | 1 | 2023 | 76 | 0.210 |
Why?
| | Cholecystitis, Acute | 1 | 2022 | 23 | 0.200 |
Why?
| | Self Expandable Metallic Stents | 1 | 2022 | 16 | 0.200 |
Why?
| | Prosthesis Implantation | 2 | 2019 | 153 | 0.190 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1000 | 0.190 |
Why?
| | Pain | 3 | 2022 | 756 | 0.190 |
Why?
| | Pain Measurement | 1 | 2024 | 521 | 0.190 |
Why?
| | Choledochostomy | 1 | 2022 | 11 | 0.190 |
Why?
| | Plastics | 2 | 2022 | 42 | 0.190 |
Why?
| | Multiple Myeloma | 1 | 2005 | 252 | 0.190 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 350 | 0.180 |
Why?
| | Multivariate Analysis | 3 | 2021 | 1509 | 0.180 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 310 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2020 | 94 | 0.180 |
Why?
| | United States | 9 | 2017 | 14841 | 0.180 |
Why?
| | Tegafur | 1 | 2020 | 3 | 0.170 |
Why?
| | Oxonic Acid | 1 | 2020 | 5 | 0.170 |
Why?
| | Lasers | 1 | 2021 | 130 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1477 | 0.160 |
Why?
| | Dissection | 2 | 2018 | 52 | 0.160 |
Why?
| | Logistic Models | 3 | 2021 | 2074 | 0.160 |
Why?
| | Living Donors | 1 | 2022 | 295 | 0.160 |
Why?
| | ROC Curve | 2 | 2018 | 554 | 0.160 |
Why?
| | Fiducial Markers | 1 | 2019 | 9 | 0.160 |
Why?
| | Hydrogen Peroxide | 1 | 2021 | 328 | 0.160 |
Why?
| | Urinary Calculi | 1 | 2019 | 12 | 0.160 |
Why?
| | Carcinoembryonic Antigen | 2 | 2018 | 39 | 0.150 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 35 | 0.150 |
Why?
| | Severity of Illness Index | 2 | 2022 | 2828 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2004 | 683 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2019 | 3284 | 0.150 |
Why?
| | Anastomosis, Surgical | 1 | 2019 | 153 | 0.150 |
Why?
| | Risk Factors | 6 | 2024 | 10388 | 0.150 |
Why?
| | Lasers, Solid-State | 1 | 2018 | 22 | 0.150 |
Why?
| | Journal Impact Factor | 1 | 2018 | 28 | 0.140 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 21 | 0.140 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2018 | 52 | 0.140 |
Why?
| | Fiber Optic Technology | 2 | 2015 | 22 | 0.140 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 12 | 0.140 |
Why?
| | Hospitals, University | 1 | 2018 | 182 | 0.140 |
Why?
| | Parkinsonian Disorders | 1 | 2017 | 35 | 0.140 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1483 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1079 | 0.130 |
Why?
| | Urinary Incontinence | 1 | 2017 | 66 | 0.130 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 77 | 0.130 |
Why?
| | Narrow Band Imaging | 1 | 2016 | 14 | 0.130 |
Why?
| | Education, Medical, Graduate | 2 | 2019 | 486 | 0.130 |
Why?
| | Feasibility Studies | 4 | 2018 | 956 | 0.130 |
Why?
| | Reoperation | 1 | 2019 | 573 | 0.130 |
Why?
| | Time Factors | 3 | 2019 | 6828 | 0.130 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 116 | 0.130 |
Why?
| | Regression Analysis | 1 | 2018 | 1024 | 0.120 |
Why?
| | Gastric Bypass | 1 | 2017 | 119 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 27 | 0.120 |
Why?
| | Neoplasm Staging | 6 | 2013 | 1389 | 0.120 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 13 | 0.120 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 13 | 0.120 |
Why?
| | Periodicals as Topic | 1 | 2018 | 211 | 0.120 |
Why?
| | Pathology, Clinical | 1 | 2015 | 36 | 0.120 |
Why?
| | Radio Waves | 1 | 2015 | 18 | 0.120 |
Why?
| | Single-Blind Method | 1 | 2016 | 282 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 306 | 0.120 |
Why?
| | Pancreaticoduodenectomy | 1 | 2016 | 164 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2804 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 1692 | 0.110 |
Why?
| | Fluoroscopy | 3 | 2019 | 154 | 0.110 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 160 | 0.100 |
Why?
| | Europe | 1 | 2014 | 414 | 0.100 |
Why?
| | Length of Stay | 1 | 2019 | 1215 | 0.100 |
Why?
| | Disinfection | 2 | 2018 | 124 | 0.100 |
Why?
| | Double-Balloon Enteroscopy | 1 | 2013 | 1 | 0.100 |
Why?
| | Databases, Factual | 1 | 2018 | 1357 | 0.100 |
Why?
| | Cyst Fluid | 2 | 2018 | 25 | 0.090 |
Why?
| | Colonoscopy | 2 | 2018 | 245 | 0.090 |
Why?
| | Parkinson Disease | 1 | 2017 | 493 | 0.090 |
Why?
| | Academic Medical Centers | 2 | 2017 | 512 | 0.090 |
Why?
| | Referral and Consultation | 2 | 2016 | 786 | 0.090 |
Why?
| | Technology Assessment, Biomedical | 2 | 2008 | 33 | 0.090 |
Why?
| | Deoxycytidine | 2 | 2013 | 179 | 0.090 |
Why?
| | Chemoradiotherapy | 1 | 2013 | 225 | 0.090 |
Why?
| | Esophageal Neoplasms | 2 | 2005 | 321 | 0.090 |
Why?
| | Catheter Ablation | 1 | 2015 | 350 | 0.090 |
Why?
| | Cohort Studies | 2 | 2014 | 5742 | 0.090 |
Why?
| | Biopsy, Fine-Needle | 2 | 2008 | 68 | 0.090 |
Why?
| | Carcinoma | 1 | 2013 | 240 | 0.090 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 119 | 0.090 |
Why?
| | Child | 4 | 2018 | 21935 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 822 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1587 | 0.080 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2008 | 179 | 0.080 |
Why?
| | Palliative Care | 2 | 2009 | 758 | 0.080 |
Why?
| | Colorado | 2 | 2018 | 4565 | 0.080 |
Why?
| | Abdominal Abscess | 1 | 2009 | 27 | 0.080 |
Why?
| | Colonography, Computed Tomographic | 1 | 2009 | 8 | 0.080 |
Why?
| | Capsule Endoscopy | 1 | 2008 | 18 | 0.070 |
Why?
| | Risk Assessment | 4 | 2016 | 3457 | 0.070 |
Why?
| | Decompression, Surgical | 1 | 2009 | 106 | 0.070 |
Why?
| | Prognosis | 3 | 2016 | 4030 | 0.070 |
Why?
| | Intestinal Perforation | 1 | 2008 | 46 | 0.070 |
Why?
| | Duodenum | 1 | 2008 | 78 | 0.070 |
Why?
| | Gastric Mucosa | 1 | 2008 | 55 | 0.070 |
Why?
| | V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2008 | 6 | 0.070 |
Why?
| | Tissue Fixation | 1 | 2008 | 36 | 0.070 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2008 | 32 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 2008 | 65 | 0.070 |
Why?
| | Equipment Safety | 4 | 2008 | 37 | 0.070 |
Why?
| | Balloon Occlusion | 1 | 2008 | 34 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 219 | 0.070 |
Why?
| | Medical Records Systems, Computerized | 1 | 2008 | 96 | 0.070 |
Why?
| | Coloring Agents | 1 | 2007 | 87 | 0.070 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2008 | 142 | 0.070 |
Why?
| | Rectal Neoplasms | 1 | 2008 | 149 | 0.070 |
Why?
| | Image Enhancement | 1 | 2008 | 190 | 0.070 |
Why?
| | Duodenoscopy | 1 | 2006 | 7 | 0.060 |
Why?
| | Liver | 2 | 2005 | 1943 | 0.060 |
Why?
| | Laser Coagulation | 1 | 2006 | 68 | 0.060 |
Why?
| | Intestinal Mucosa | 2 | 2008 | 623 | 0.060 |
Why?
| | Prosthesis Design | 2 | 2009 | 327 | 0.060 |
Why?
| | Anesthesia, General | 1 | 2006 | 77 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2691 | 0.060 |
Why?
| | Conscious Sedation | 1 | 2006 | 92 | 0.060 |
Why?
| | Ascites | 1 | 2005 | 46 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 37 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1007 | 0.060 |
Why?
| | Administration, Rectal | 1 | 2024 | 11 | 0.060 |
Why?
| | Equipment Failure | 1 | 2005 | 108 | 0.060 |
Why?
| | Pain Management | 1 | 2008 | 352 | 0.060 |
Why?
| | Growth Substances | 1 | 2004 | 147 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2013 | 220 | 0.050 |
Why?
| | Infant | 1 | 2018 | 9465 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2005 | 211 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2013 | 389 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2006 | 316 | 0.050 |
Why?
| | International Cooperation | 2 | 2017 | 198 | 0.050 |
Why?
| | Child, Preschool | 1 | 2018 | 11074 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 658 | 0.050 |
Why?
| | Pilot Projects | 1 | 2008 | 1710 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2003 | 110 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 246 | 0.050 |
Why?
| | Odds Ratio | 2 | 2016 | 1070 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1236 | 0.040 |
Why?
| | Anti-Infective Agents, Local | 1 | 2021 | 40 | 0.040 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2004 | 262 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 343 | 0.040 |
Why?
| | Disease-Free Survival | 2 | 2013 | 686 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1993 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2013 | 889 | 0.040 |
Why?
| | Myotomy | 1 | 2018 | 13 | 0.040 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 25 | 0.040 |
Why?
| | Equipment Contamination | 1 | 2018 | 67 | 0.040 |
Why?
| | Republic of Korea | 1 | 2017 | 37 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 816 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2018 | 51 | 0.030 |
Why?
| | Bile | 2 | 2009 | 34 | 0.030 |
Why?
| | Autopsy | 1 | 2017 | 95 | 0.030 |
Why?
| | Prosthesis Failure | 2 | 2009 | 123 | 0.030 |
Why?
| | Surgery, Computer-Assisted | 1 | 2018 | 101 | 0.030 |
Why?
| | Colonic Polyps | 1 | 2018 | 88 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 318 | 0.030 |
Why?
| | Cytokines | 1 | 2004 | 2085 | 0.030 |
Why?
| | Hospitalization | 1 | 2006 | 2199 | 0.030 |
Why?
| | Videotape Recording | 1 | 2016 | 35 | 0.030 |
Why?
| | Barrett Esophagus | 1 | 2018 | 149 | 0.030 |
Why?
| | Gastroenterologists | 1 | 2016 | 18 | 0.030 |
Why?
| | Radiologists | 1 | 2016 | 51 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 307 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2017 | 224 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2016 | 81 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 5778 | 0.030 |
Why?
| | Phantoms, Imaging | 1 | 2016 | 152 | 0.030 |
Why?
| | Societies, Medical | 2 | 2008 | 820 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 628 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2018 | 351 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2013 | 45 | 0.030 |
Why?
| | Leucovorin | 1 | 2013 | 81 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 34 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2013 | 72 | 0.020 |
Why?
| | Program Evaluation | 1 | 2017 | 898 | 0.020 |
Why?
| | Camptothecin | 1 | 2013 | 116 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1622 | 0.020 |
Why?
| | Treatment Failure | 1 | 2013 | 356 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 53 | 0.020 |
Why?
| | Quinazolines | 1 | 2013 | 251 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2011 | 115 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 786 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2013 | 404 | 0.020 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 806 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2844 | 0.020 |
Why?
| | Stainless Steel | 1 | 2009 | 20 | 0.020 |
Why?
| | Hematoma | 1 | 2009 | 53 | 0.020 |
Why?
| | Alloys | 1 | 2009 | 35 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 343 | 0.020 |
Why?
| | Terminally Ill | 1 | 2009 | 37 | 0.020 |
Why?
| | Medical Laboratory Science | 1 | 2008 | 9 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 92 | 0.020 |
Why?
| | Miniaturization | 1 | 2008 | 22 | 0.020 |
Why?
| | Ligation | 1 | 2008 | 92 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Probability | 1 | 2009 | 304 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 44 | 0.020 |
Why?
| | Total Quality Management | 1 | 2008 | 61 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 2008 | 180 | 0.020 |
Why?
| | Forms and Records Control | 1 | 2008 | 23 | 0.020 |
Why?
| | Esophageal and Gastric Varices | 1 | 2008 | 40 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2008 | 268 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 324 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 288 | 0.020 |
Why?
| | Safety Management | 1 | 2008 | 124 | 0.020 |
Why?
| | Diarrhea | 1 | 2008 | 184 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 189 | 0.020 |
Why?
| | Injections | 1 | 2007 | 183 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2007 | 213 | 0.020 |
Why?
| | Survival Analysis | 1 | 2009 | 1325 | 0.020 |
Why?
| | DNA | 1 | 2013 | 1459 | 0.020 |
Why?
| | Information Dissemination | 1 | 2008 | 218 | 0.020 |
Why?
| | Safety | 1 | 2007 | 338 | 0.010 |
Why?
| | Patient Selection | 1 | 2009 | 696 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 2006 | 143 | 0.010 |
Why?
| | Receptors, Interleukin-8B | 1 | 2004 | 26 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 2992 | 0.010 |
Why?
| | Recurrence | 1 | 2007 | 1060 | 0.010 |
Why?
| | Esophagectomy | 1 | 2005 | 131 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 1972 | 0.010 |
Why?
| | Swine | 1 | 2006 | 775 | 0.010 |
Why?
| | Positron-Emission Tomography | 1 | 2005 | 294 | 0.010 |
Why?
| | Ischemia | 1 | 2004 | 409 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2004 | 1096 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4193 | 0.010 |
Why?
| | Biomarkers | 1 | 2008 | 4149 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2006 | 4295 | 0.010 |
Why?
| | Animals | 1 | 2006 | 36940 | 0.000 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|